Patents Assigned to CureVac Real Estate GmbH
-
Publication number: 20230053382Abstract: The present invention relates to a method for producing RNA. In particular, the present invention relates to a method for producing RNA, which is scalable and provides RNA at a high purity. The present invention provides a method for producing RNA under GMP and/or cGMP-compliant conditions. The invention further provides specific processes for use as a quality control in the manufacturing of a template DNA and/or in a method for producing RNA, in particular by in vitro transcription.Type: ApplicationFiled: July 21, 2022Publication date: February 23, 2023Applicant: CureVac Real Estate GmbHInventors: Florian VON DER MÜLBE, Ladislaus REIDEL, Thomas KETTERER, Lilia GONTCHAROVA, Susanne BAUER, Steve PASCOLO, Jochen PROBST, Andreas SCHMID
-
Publication number: 20220325273Abstract: The present invention relates to method for producing and purifying RNA comprising the steps of providing DNA encoding the RNA; transcription of the DNA into RNA; and conditioning and/or purifying of the solution comprising transcribed RNA by one or more steps of tangential flow filtration (TFF).Type: ApplicationFiled: February 3, 2022Publication date: October 13, 2022Applicant: CureVac Real Estate GmbHInventors: Andreas FUNKNER, Stefanie DORNER, Stefanie SEWING, Johannes KAMM, Norbert BROGHAMMER, Thomas KETTERER, Thorsten MUTZKE
-
Patent number: 11446250Abstract: The present invention is directed to the field of RNA formulation, in particular to lyophilization of RNA. The invention provides a method for lyophilization of RNA. The present invention further concerns a lyophilized composition obtainable by the inventive method, a pharmaceutical composition, a vaccine and a kit or kit of parts. Moreover, the present invention provides a novel use of a lyoprotectant for lyophilizing RNA, the use of the inventive method in the manufacture of a medicament as well as the first and second medical use of the composition obtainable by the inventive method, the pharmaceutical composition, the vaccine or the kit or kit of parts according to the invention.Type: GrantFiled: August 17, 2020Date of Patent: September 20, 2022Assignee: CureVac Real Estate GmbHInventors: Thomas Ketterer, Thorsten Mutzke, Michael Wiggenhorn, Frank Schaubhut, Florian Von Der Mülbe
-
Publication number: 20220160638Abstract: The present invention is directed to the field of RNA formulation, in particular to lyophilization of RNA. The invention provides a method for lyophilization of RNA. The present invention further concerns a lyophilized composition obtainable by the inventive method, a pharmaceutical composition, a vaccine and a kit or kit of parts. Moreover, the present invention provides a novel use of a lyoprotectant for lyophilizing RNA, the use of the inventive method in the manufacture of a medicament as well as the first and second medical use of the composition obtainable by the inventive method, the pharmaceutical composition, the vaccine or the kit or kit of parts according to the invention.Type: ApplicationFiled: December 5, 2021Publication date: May 26, 2022Applicant: CureVac Real Estate GmbHInventors: Thomas KETTERER, Thorsten MUTZKE, Michael WIGGENHORN, Frank SCHAUBHUT, Florian VON DER MÜLBE
-
Publication number: 20220154253Abstract: The present invention relates to a method for producing RNA. In particular, the present invention relates to a method for producing RNA, which is scalable and provides RNA at a high purity. The present invention provides a method for producing RNA under GMP and/or cGMP-compliant conditions. The invention further provides specific processes for use as a quality control in the manufacturing of a template DNA and/or in a method for producing RNA, in particular by in vitro transcription.Type: ApplicationFiled: January 31, 2022Publication date: May 19, 2022Applicant: CureVac Real Estate GmbHInventors: Florian VON DER MÜLBE, Ladislaus REIDEL, Thomas KETTERER, Lilia GONTCHAROVA, Susanne BAUER, Steve PASCOLO, Jochen PROBST, Andreas SCHMID
-
Patent number: 11274293Abstract: The present invention relates to method for producing and purifying RNA comprising the steps of providing DNA encoding the RNA; transcription of the DNA into RNA; and conditioning and/or purifying of the solution comprising transcribed RNA by one or more steps of tangential flow filtration (TFF).Type: GrantFiled: July 21, 2020Date of Patent: March 15, 2022Assignee: CureVac Real Estate GmbHInventors: Andreas Funkner, Stefanie Dorner, Stefanie Sewing, Johannes Kamm, Norbert Broghammer, Thomas Ketterer, Thorsten Mutzke
-
Patent number: 11268157Abstract: The present invention relates to a method for producing RNA. In particular, the present invention relates to a method for producing RNA, which is scalable and provides RNA at a high purity. The present invention provides a method for producing RNA under GMP and/or cGMP-compliant conditions. The invention further provides specific processes for use as a quality control in the manufacturing of a template DNA and/or in a method for producing RNA, in particular by in vitro transcription.Type: GrantFiled: June 2, 2020Date of Patent: March 8, 2022Assignee: CureVac Real Estate GmbHInventors: Florian Von Der Mülbe, Ladislaus Reidel, Thomas Ketterer, Lilia Gontcharova, Susanne Bauer, Steve Pascolo, Jochen Probst, Andreas Schmid
-
Publication number: 20210040473Abstract: The present invention relates to method for producing and purifying RNA comprising the steps of providing DNA encoding the RNA; transcription of the DNA into RNA; and conditioning and/or purifying of the solution comprising transcribed RNA by one or more steps of tangential flow filtration (TFF).Type: ApplicationFiled: July 21, 2020Publication date: February 11, 2021Applicant: CureVac Real Estate GmbHInventors: Andreas FUNKNER, Stefanie DORNER, Stefanie SEWING, Johannes KAMM, Norbert BROGHAMMER, Thomas KETTERER, Thorsten MUTZKE
-
Publication number: 20210040526Abstract: The present invention relates to a method for synthesizing an RNA molecule of a given sequence, comprising the step of determining the fraction (1) for each of the four nucleotides G, A, C and U in said RNA molecule, and the step of synthesizing said RNA molecule by in vitro transcription in a sequence-optimized reaction mix, wherein said sequence-optimized reaction mix comprises the four ribonucleoside triphosphates GTP, ATP, CTP and UTP, wherein the fraction (2) of each of the four ribonucleoside triphosphates in the sequence-optimized reaction mix corresponds to the fraction (1) of the respective nucleotide in said RNA molecule, a buffer, a DNA template, and an RNA polymerase.Type: ApplicationFiled: October 15, 2020Publication date: February 11, 2021Applicant: CureVac Real Estate GmbHInventors: Aniela WOCHNER, Tilmann ROOS, Thomas KETTERER
-
Publication number: 20200383922Abstract: The present invention is directed to the field of RNA formulation, in particular to lyophilization of RNA. The invention provides a method for lyophilization of RNA. The present invention further concerns a lyophilized composition obtainable by the inventive method, a pharmaceutical composition, a vaccine and a kit or kit of parts. Moreover, the present invention provides a novel use of a lyoprotectant for lyophilizing RNA, the use of the inventive method in the manufacture of a medicament as well as the first and second medical use of the composition obtainable by the inventive method, the pharmaceutical composition, the vaccine or the kit or kit of parts according to the invention.Type: ApplicationFiled: August 17, 2020Publication date: December 10, 2020Applicant: CureVac Real Estate GmbHInventors: Thomas KETTERER, Thorsten MUTZKE, Michael WIGGENHORN, Frank SCHAUBHUT, Florian VON DER MÜLBE
-
Patent number: 10837039Abstract: The present invention relates to a method for synthesizing an RNA molecule of a given sequence, comprising the step of determining the fraction (1) for each of the four nucleotides G, A, C and U in said RNA molecule, and the step of synthesizing said RNA molecule by in vitro transcription in a sequence-optimized reaction mix, wherein said sequence-optimized reaction mix comprises the four ribonucleoside triphosphates GTP, ATP, CTP and UTP, wherein the fraction (2) of each of the four ribonucleoside triphosphates in the sequence-optimized reaction mix corresponds to the fraction (1) of the respective nucleotide in said RNA molecule, a buffer, a DNA template, and an RNA polymerase.Type: GrantFiled: June 10, 2015Date of Patent: November 17, 2020Assignee: CureVac Real Estate GmbHInventors: Aniela Wochner, Tilmann Roos, Thomas Ketterer
-
Publication number: 20200308634Abstract: The present invention relates to a method for producing RNA. In particular, the present invention relates to a method for producing RNA, which is scalable and provides RNA at a high purity. The present invention provides a method for producing RNA under GMP and/or cGMP-compliant conditions. The invention further provides specific processes for use as a quality control in the manufacturing of a template DNA and/or in a method for producing RNA, in particular by in vitro transcription.Type: ApplicationFiled: June 2, 2020Publication date: October 1, 2020Applicant: CureVac Real Estate GmbHInventors: Florian VON DER MÜLBE, Ladislaus REIDEL, Thomas KETTERER, Lilia GONTCHAROVA, Susanne BAUER, Steve PASCOLO, Jochen PROBST, Andreas SCHMID
-
Patent number: 10780054Abstract: The present invention is directed to the field of RNA formulation, in particular to lyophilization of RNA. The invention provides a method for lyophilization of RNA. The present invention further concerns a lyophilized composition obtainable by the inventive method, a pharmaceutical composition, a vaccine and a kit or kit of parts. Moreover, the present invention provides a novel use of a lyoprotectant for lyophilizing RNA, the use of the inventive method in the manufacture of a medicament as well as the first and second medical use of the composition obtainable by the inventive method, the pharmaceutical composition, the vaccine or the kit or kit of parts according to the invention.Type: GrantFiled: April 15, 2016Date of Patent: September 22, 2020Assignee: CureVac Real Estate GmbHInventors: Thomas Ketterer, Thorsten Mutzke, Michael Wiggenhorn, Frank Schaubhut, Florian Von Der Mülbe
-
Patent number: 10760070Abstract: The present invention relates to method for producing and purifying RNA comprising the steps of providing DNA encoding the RNA; transcription of the DNA into RNA; and conditioning and/or purifying of the solution comprising transcribed RNA by one or more steps of tangential flow filtration (TFF).Type: GrantFiled: May 30, 2016Date of Patent: September 1, 2020Assignee: CureVac Real Estate GmbHInventors: Andreas Funkner, Stefanie Dorner, Stefanie Sewing, Johannes Kamm, Norbert Broghammer, Thomas Ketterer, Thorsten Mutzke
-
Publication number: 20200246451Abstract: The present invention relates to a method for producing a liquid composition comprising a nanoparticle comprising at least one RNA and at least one cationic or polycationic compound, advantageously on a large scale suitable for pharmaceutical applications. The present invention further concerns the use of the inventive method in the manufacture of a medicament or a vaccine. Furthermore, the invention relates to compositions containing the RNA-comprising nanoparticle, and to pharmaceutical compositions comprising the same.Type: ApplicationFiled: April 2, 2020Publication date: August 6, 2020Applicant: CureVac Real Estate GmbHInventors: Thorsten MUTZKE, Markus KREUZ, Stefanie SEWING, Fabian Johannes EBER, Wenke WAGNER, Michael SONNTAG, Michael WIGGENHORN, Katharina KOLLAND
-
Patent number: 10711315Abstract: The present invention relates to a method for producing RNA. In particular, the present invention relates to a method for producing RNA, which is scalable and provides RNA at a high purity. The present invention provides a method for producing RNA under GMP and/or cGMP-compliant conditions. The invention further provides specific processes for use as a quality control in the manufacturing of a template DNA and/or in a method for producing RNA, in particular by in vitro transcription.Type: GrantFiled: June 11, 2018Date of Patent: July 14, 2020Assignee: CureVac Real Estate GmbHInventors: Florian Von Der Mülbe, Ladislaus Reidel, Thomas Ketterer, Lilia Gontcharova, Susanne Bauer, Steve Pascolo, Jochen Probst, Andreas Schmid
-
Publication number: 20200216878Abstract: The present invention relates to the field of RNA analysis. In particular, the invention concerns the use of a catalytic nucleic acid molecule for the analysis of an RNA molecule. The invention concerns methods for analyzing the 5? terminal structures of an RNA molecule having a cleavage site for a catalytic nucleic acid molecule.Type: ApplicationFiled: March 4, 2020Publication date: July 9, 2020Applicant: CureVac Real Estate GmbHInventor: Aniela WOCHNER
-
Patent number: 10653768Abstract: The present invention relates to a method for producing a liquid composition comprising a nanoparticle comprising at least one RNA and at least one cationic or polycationic compound, advantageously on a large scale suitable for pharmaceutical applications. The present invention further concerns the use of the inventive method in the manufacture of a medicament or a vaccine. Furthermore, the invention relates to compositions containing the RNA-comprising nanoparticle, and to pharmaceutical compositions comprising the same.Type: GrantFiled: April 13, 2016Date of Patent: May 19, 2020Assignee: CureVac Real Estate GmbHInventors: Thorsten Mutzke, Markus Kreuz, Stefanie Sewing, Fabian Johannes Eber, Wenke Wagner, Michael Sonntag, Michael Wiggenhorn, Katharina Kolland
-
Patent number: 10648017Abstract: The present invention relates to the field of RNA analysis. In particular, the invention concerns the use of a catalytic nucleic acid molecule for the analysis of an RNA molecule. The invention concerns methods for analyzing the 5? terminal structures of an RNA molecule having a cleavage site for a catalytic nucleic acid molecule.Type: GrantFiled: June 28, 2016Date of Patent: May 12, 2020Assignee: CureVac Real Estate GmbHInventor: Aniela Wochner